PhRMA Defends Standing Before Fifth Circuit in Drug Price Battle

A leading pharmaceutical industry group is urging a federal appeals court to rule it has standing to challenge the constitutionality of a government drug price-setting program after a lower court dismissed the case.

The Pharmaceutical Research and Manufacturers of America, along with plaintiffs National Infusion Center Association and Global Colon Cancer Association, are asking the US Court of Appeals for the Fifth Circuit to reverse a lower court decision in its case against the Medicare drug price negotiation program.

The groups’ case is part of the slew of lawsuits challenging President Joe Biden’s program, created under the 2022 Inflation Reduction ...